BB Medtech Ag

Orion Oyj (HEL:ORN1V) Orion Corporation will publish its financial result for 2008 on Friday, 6 February 2009.

Orion Oyj (HEL:ORN1V) Orion Corporation will publish its Interim Report for the period of January-September 2008 on Tuesday 28 October 2008 at 8:30 EET. The release and the presentation material will be available after publication on the Group's homepage at www.orion.fi/investors.

Orion Oyj (HEL:ORN1V) Company states the realisation of generic competition is still neither certain nor imminent

Orion Oyj (HEL:ORN1V) With this release, Orion Corporation updates information provided earlier on the Phase III clinical studies which are under way with dexmedetomidine, a sedative for patients in intensive care, with an aim to have the product registered in Europe as a long-term infusion, administered for over 24 hours. In these studies, the efficacy and safety of dexmedetomidine is compared with sedatives currently used in intensive care, i.e. midazolam in the MIDEX study and propofol in the PRODEX study, altogether in approximately 1,000 patients.

Orion Oyj Steady growth continued

Orion Oyj In accordance with Section 3 of the Articles of Association of Orion Corporation, 500,000 A-shares have been converted into 500,000 B-shares. The conversion has been entered into the Trade Register on 28 July 2008. After the conversion there are 51,440,668 A-shares and 89,817,160 B-shares in the company.

Orion Oyj Orion Corporation will publish its Interim Report for the period of January-June 2008 on Tuesday, 5 August 2008. The estimated time of disclosure is 12.00 Finnish time. The release and the presentation material will be available after publishing on the Group's homepage at www.orion.fi/investors.

Orion Oyj In accordance with Section 3 of the Articles of Association of Orion Corporation, 520,000 A-shares have been converted into 520,000 B-shares. The conversion has been entered into the Trade Register on 16 June 2008. After the conversion there are 51,940,668 A-shares and 89,317,160 B-shares in the company.

Orion Oyj Licensing agreement strengthens Orion's urological and oncological portfolio in the Nordic markets and Switzerland